We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00217932
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : January 12, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) versus placebo in treating children with temper outbursts and severe mood disorders.

Condition or disease Intervention/treatment Phase
Mood Disorders Drug: Divalproex Sodium (Depakote) Phase 2

Detailed Description:

Depakote has been used to treat seizures in children for more than 20 years. The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) in treating children with temper outbursts and severe mood disorders.

This study will last 12 weeks. Participants will be randomly assigned to receive either 250 mg Depakote or placebo. The dose of medication will increase at the end of Week 1 to 500 mg of either depakote or placebo; participants will remain on this dose through Week 5. At Week 6, participants will cross-over and receive the other treatment (either depakote or placebo), which they will take through Week 12. Study visits will occur weekly and will include a physical exam, blood and urine tests, and self-reports of adverse events. In addition, caregivers will complete reports about mood swings throughout the study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings
Study Start Date : September 2000
Estimated Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mood Disorders
U.S. FDA Resources

Primary Outcome Measures :
  1. Reduction in symptoms of explosive mood disorder; measured throughout the study and at Week 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   7 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets criteria for Explosive Mood Disorder (EMD)
  • Explosive temper as evidenced by four or more outbursts of rage, property destruction, or fighting per month
  • Mood liability as evidenced by multiple, daily, distinct shifts from normal to irritable mood with withdrawn or boisterous behavior, occurring without a clear precipitant
  • History of an EMD for one year without treatment
  • EMD symptoms resulting in impairment in two or more of the following areas: school, the law, family, substance use, peers, or work
  • EMD symptoms do not occur only during substance toxicity or withdrawal
  • EMD symptoms are not confined to a single setting or context
  • Parent and child willing to consent to study
  • Inadequate response to an adequate trial (8 weeks) of psychotherapy and/or family therapy

Exclusion Criteria:

  • Meets criteria for pervasive developmental disorder or childhood schizophrenia
  • Seizure or other neurologic disturbance
  • Pregnant
  • Moderate to severe mental retardation
  • Physical exam or laboratory results with significant abnormalities
  • Positive Hepatitis screen test
  • Liver dysfunction
  • Active suicidal or homicidal ideation
  • History of suicide attempts
  • History of barbiturate use
  • Unequivocal manic or hypomanic episode
  • Meets criteria for attention deficit hyperactivity disorder (ADHD) and has not failed a trial of psychostimulants for ADHD
  • Meets criteria for major depression in prepuberty
  • If female, unwilling to use an effective method of contraception for the duration of the study
  • Mitochondrial disease or family history of mitochondrial disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00217932

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Stephen Donovan, MD Columbia University

ClinicalTrials.gov Identifier: NCT00217932     History of Changes
Other Study ID Numbers: NIDA-00451-1
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: April 2006

Keywords provided by National Institute on Drug Abuse (NIDA):
Behavioral Disorders

Additional relevant MeSH terms:
Mood Disorders
Mental Disorders
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs